U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C22H22NO4S2.Ca
Molecular Weight 897.167
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOFENOPRIL CALCIUM

SMILES

[Ca++].C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C([O-])=O)SC3=CC=CC=C3.C[C@H](CSC(=O)C4=CC=CC=C4)C(=O)N5C[C@H](C[C@H]5C([O-])=O)SC6=CC=CC=C6

InChI

InChIKey=NSYUKKYYVFVMST-LETVYOFWSA-L
InChI=1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1

HIDE SMILES / InChI
Zofenopril is an inhibitor of Angiotensin Converting Enzyme (ACE), which is approved in Europe for the treatment of hypertension and acute myocardial infarction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P12821
Gene ID: 1636.0
Gene Symbol: ACE
Target Organism: Homo sapiens (Human)
10.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOPRANOL

Approved Use

ZOPRANOL is indicated for the treatment of mild to moderate essential hypertension.

Launch Date

2000
Primary
ZOPRANOL

Approved Use

ZOPRANOL is indicated for the treatment initiated within the first 24 hours of patients with acute myocardial infarction with or without signs and symptoms of heart failure.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
1989
Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension.
1989 Mar
Zofenopril after anterior myocardial infarction.
1995 Jun 22
Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model.
2009 Jun 9
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4).
2012
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
2016 Jul 5
Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies.
2017 Jan
Patents

Sample Use Guides

The usual effective dose in hypertension is 30 mg/day (in patients without volume or salt depletion) and the starting dose is 7.5 or 15 mg/day (in patients with volume or salt depletion). In acute myocardial infarction the treatment scheme is the following: 7.5 mg every 12 h (1st and 2nd day); 15 mg every 12 h (3rd and 4th day); 30 mg every 12 h (from 5th day).
Route of Administration: Oral
Zofenopril (36 uM) significantly increased coronary flow after 5 min of incubation with isolated rat hearts.
Name Type Language
ZOFENOPRIL CALCIUM
MART.   USAN   WHO-DD  
USAN  
Official Name English
ZOFENOPRIL CALCIUM SALT
MI  
Common Name English
ZOPRACE
Brand Name English
(4S)-N-((S)-3-MERCAPTO-2-METHYLPROPIONYL)-4-(PHENYLTHIO)-R-PROLINE BENZOATE (ESTER), CALCIUM SALT
Common Name English
ZOFENOPRIL CALCIUM [MART.]
Common Name English
ZOFENOPRIL CALCIUM [USAN]
Common Name English
SQ-26991
Code English
SQ 26991
Code English
Zofenopril calcium [WHO-DD]
Common Name English
ZOFENOPRIL CALCIUM SALT [MI]
Common Name English
R-PROLINE, 1-(3-(BENZOYLTHIO)-2-METHYL-1-OXOPROPYL)-4-(PHENYLTHIO)-, CALCIUM SALT, (1(R*),2.ALPHA.,4.ALPHA.)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C247
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
Code System Code Type Description
USAN
U-63
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
DRUG BANK
DBSALT002196
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
MERCK INDEX
m11656
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY Merck Index
RXCUI
259493
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY RxNorm
FDA UNII
88ZQ329PU2
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
SMS_ID
100000091302
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
EVMPD
SUB05191MIG
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
PUBCHEM
3033690
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
CHEBI
82600
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
NCI_THESAURUS
C82220
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
CAS
81938-43-4
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048625
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL331378
Created by admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
PRIMARY